{"title":"Research progress of 18F-Flurpiridaz PET myocardial perfusion imaging","authors":"Jiao Wang, Jianming Li, Shuai Li","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.09.013","DOIUrl":null,"url":null,"abstract":"PET myocardial perfusion imaging (MPI) is increasingly used in non-invasive detection and evaluation of coronary artery disease (CAD). However, the wide application of common PET MPI agents (15O-H2O, 13N-NH3·H2O, 82Rb) in clinic is limited by their inherent shortcomings. The development of 18F-Flurpiridaz has opened up a new field of positron blood flow imaging agents. Preliminary results of pre-clinical and clinical trials showed that 18F-Flurpiridaz has important properties (high myocardial uptake, high resolution of perfusion defect, slow myocardial clearance, stable target/non-target ratio, and the ability of quantitative myocardial flow analysis) as an ideal PET MPI agent, so it has a good clinical application prospect. In this paper, the present application and progress of 18F-Flurpiridaz PET MPI are reviewed. \n \n \nKey words: \nMyocardial perfusion imaging; Positron-emission tomography; Pyridazines; Fluorine radioisotopes; Trends","PeriodicalId":10099,"journal":{"name":"中华核医学与分子影像杂志","volume":"39 1","pages":"557-559"},"PeriodicalIF":0.0000,"publicationDate":"2019-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华核医学与分子影像杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.09.013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
PET myocardial perfusion imaging (MPI) is increasingly used in non-invasive detection and evaluation of coronary artery disease (CAD). However, the wide application of common PET MPI agents (15O-H2O, 13N-NH3·H2O, 82Rb) in clinic is limited by their inherent shortcomings. The development of 18F-Flurpiridaz has opened up a new field of positron blood flow imaging agents. Preliminary results of pre-clinical and clinical trials showed that 18F-Flurpiridaz has important properties (high myocardial uptake, high resolution of perfusion defect, slow myocardial clearance, stable target/non-target ratio, and the ability of quantitative myocardial flow analysis) as an ideal PET MPI agent, so it has a good clinical application prospect. In this paper, the present application and progress of 18F-Flurpiridaz PET MPI are reviewed.
Key words:
Myocardial perfusion imaging; Positron-emission tomography; Pyridazines; Fluorine radioisotopes; Trends
期刊介绍:
Chinese Journal of Nuclear Medicine and Molecular Imaging (CJNMMI) was established in 1981, with the name of Chinese Journal of Nuclear Medicine, and renamed in 2012. As the specialized periodical in the domain of nuclear medicine in China, the aim of Chinese Journal of Nuclear Medicine and Molecular Imaging is to develop nuclear medicine sciences, push forward nuclear medicine education and basic construction, foster qualified personnel training and academic exchanges, and popularize related knowledge and raising public awareness.
Topics of interest for Chinese Journal of Nuclear Medicine and Molecular Imaging include:
-Research and commentary on nuclear medicine and molecular imaging with significant implications for disease diagnosis and treatment
-Investigative studies of heart, brain imaging and tumor positioning
-Perspectives and reviews on research topics that discuss the implications of findings from the basic science and clinical practice of nuclear medicine and molecular imaging
- Nuclear medicine education and personnel training
- Topics of interest for nuclear medicine and molecular imaging include subject coverage diseases such as cardiovascular diseases, cancer, Alzheimer’s disease, and Parkinson’s disease, and also radionuclide therapy, radiomics, molecular probes and related translational research.